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Abstract
Converging evidence leaves little doubt that a change in the conformation of prion protein (PrP
C) from a mainly a-helical to
a b-sheet rich PrP-scrapie (PrP
Sc) form is the main event responsible for prion disease associated neurotoxicity. However,
neither the mechanism of toxicity by PrP
Sc, nor the normal function of PrP
C is entirely clear. Recent reports suggest that
imbalance of iron homeostasis is a common feature of prion infected cells and mouse models, implicating redox-iron in
prion disease pathogenesis. In this report, we provide evidence that PrP
C mediates cellular iron uptake and transport, and
mutant PrP forms alter cellular iron levels differentially. Using human neuroblastoma cells as models, we demonstrate that
over-expression of PrP
C increases intra-cellular iron relative to non-transfected controls as indicated by an increase in total
cellular iron, the cellular labile iron pool (LIP), and iron content of ferritin. As a result, the levels of iron uptake proteins
transferrin (Tf) and transferrin receptor (TfR) are decreased, and expression of iron storage protein ferritin is increased. The
positive effect of PrP
C on ferritin iron content is enhanced by stimulating PrP
C endocytosis, and reversed by cross-linking
PrP
C on the plasma membrane. Expression of mutant PrP forms lacking the octapeptide-repeats, the membrane anchor, or
carrying the pathogenic mutation PrP
102L decreases ferritin iron content significantly relative to PrP
C expressing cells, but
the effect on cellular LIP and levels of Tf, TfR, and ferritin is complex, varying with the mutation. Neither PrP
C nor the mutant
PrP forms influence the rate or amount of iron released into the medium, suggesting a functional role for PrP
C in cellular
iron uptake and transport to ferritin, and dysfunction of PrP
C as a significant contributing factor of brain iron imbalance in
prion disorders.
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Introduction
Prion protein (PrP
C) is an evolutionarily conserved cell surface
glycoprotein expressed abundantly on neuronal cells. Despite its
ubiquitous presence, the physiological function of PrP
C has
remained ambiguous. The best characterized role for this protein
remains its involvement in the pathogenesis of familial, infectious,
and sporadic prion disorders, where a change in the conformation
of PrP
C from a mainly a-helical to a b-sheet rich PrP-scrapie
(PrP
Sc) form renders it infectious and pathogenic [1–5]. The
mechanism by which PrP
Sc induces neurotoxicity, however, is not
clear. Studies over the past decade have clarified several aspects of
this process [1,6,7]. Prominent among these is the resistance of
transgenic mice lacking neuronal PrP
C expression to PrP
Sc
induced toxicity, implicating PrP
C as the principal mediator of
the neurotoxic signal [8,9]. However, prion infected transgenic
mice expressing PrP
C only on astrocytes accumulate PrP
Sc and
succumb to disease [10], leaving the matter unresolved. Adding to
the complexity is the development of prion specific neuropathol-
ogy in mice over-expressing normal or mutant PrP in the wrong
cellular compartment in the absence of detectable PrP
Sc,
suggesting the presence of additional pathways of neurotoxicity
[1,7]. Although brain homogenates from these animals are not
infectious in bioassays, these models suggest that a disproportion-
ate change in the physiological function of PrP
C is as neurotoxic as
the gain of toxic function by PrP
Sc. Investigations on both fronts
are therefore essential to uncover the underlying mechanism(s) of
neurotoxicity in these disorders.
Efforts aimed at understanding the physiological function of
PrP
C and pathological implications thereof have revealed several
possibilities, varying with the model, the physiological state, and
the extra- and intracellular milieu in a particular tissue. Some of
the reported functions include a role in cell adhesion, signal
transduction, and as an anti-oxidant and anti-apoptotic protein
[7,11,12]. While the importance of these observations cannot be
under-estimated, they fail to provide a direct link between PrP
C
function and dysfunction to prion disease pathogenesis. In this
context, it is interesting to note that PrP
C binds iron and copper,
and is believed to play a functional role in neuronal iron and
copper metabolism [13,14]. Since both iron and copper are highly
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dysfunction of PrP
C due to aggregation to the PrP
Sc form causes
the reported accumulation of redox-active PrP
Sc complexes in
prion infected cell and mouse models, inducing a state of iron
imbalance [15–17]. A phenotype of iron deficiency in the presence
of excess iron is noted in sporadic Cruetzfeldt-Jakob disease (sCJD)
affected human and scrapie infected animal brain tissue, lending
credence to this assumption [45].
To explore if PrP
C is involved in cellular iron metabolism, we
investigated the influence of PrP
C and mutant PrP forms on
cellular iron levels in human neuroblastoma cells expressing
endogenous levels (M17) or transfected to express 6–7 fold higher
levels of PrP
C or mutant PrP forms. The following parameters
were evaluated: 1) total cellular iron, 2) intracellular labile iron
pool (LIP), 3) iron content of ferritin, and 4) levels of iron uptake
proteins transferrin receptor (TfR) and transferrin (Tf) and iron
storage protein ferritin that respond to minor changes in the LIP
[18,19]. Our data demonstrate that PrP
C increases cellular iron
levels and the cells demonstrate a state of mild overload, while
pathogenic and non-pathogenic mutations of PrP alter cellular
iron levels differentially, specific to the mutation.
Results
Normal and mutant PrP forms influence cellular iron
levels differentially
The influence of PrP expression on cellular iron status was
evaluated in M17 cells expressing endogenous PrP
C or stably
transfected to express 6–7 fold higher levels of PrP
C or the
following mutant PrP forms: 1) PrP
231stop that lacks the
glycosylphosphatidyl inositol (GPI) anchor and is secreted into
the medium, 2) PrP
D51–89 that lacks the copper binding octa-
peptide repeat region, 3) PrP
D23–89 that lacks the N-terminal 90
amino acids, and 4) PrP
102L associated with Gerstmann-Straussler-
Scheinker disease (GSS), a familial prion disorder (Fig. 1A).
Expression of PrP in transfected cell lines was assessed by
separating cell lysates on SDS-PAGE and probing transferred
proteins with the PrP specific monoclonal antibody 3F4 [26]. As
expected, the di-, mono-, and unglycosylated forms of PrP
C,
PrP
D51–89, PrP
D23–89, and PrP
102L migrating between 20 and
37 kDa are detected (Fig. 1B, lanes 2–5). Deletion mutations
PrP
D51–89 and PrP
D23–89 migrate faster than PrP
C and PrP
102L as
expected (Fig. 1B, lanes 3 and 4). M17 lysates show barely
detectable levels of PrP
C, while transfected cell lines express
significantly higher levels of PrP
C and mutant PrP forms (Fig. 1B,
lanes 1–5).
To evaluate if PrP
C or mutant PrP forms influence cellular iron
uptake, M17, PrP
C, PrP
D51–89, PrP
D23–89, and PrP
102L cells
cultured in serum-free medium for 1 hour were radiolabeled with
59FeCl3-citrate complex for 4 hours in the same medium, washed
with PBS supplemented with 100 mM desferrioxamine (DFO) to
remove surface bound iron, and lysed in non-denaturing buffer.
Equal amount of protein from lysates was spotted on a PVDF
membrane, air-dried, and exposed to an X-ray film. Surprisingly,
PrP
C and PrP
102L cells incorporate significantly more
59Fe, while
PrP
D51–89, PrP
D23–89 cells take up less
59Fe than M17 controls
(Fig. 1C).
Major
59Fe labeled proteins in these cells were identified by
separating cell lysates prepared in non-denaturing buffer on a 3–
20% native gel in duplicate. One part of the gel was dried and
subjected to autoradiography (Fig. 2, lanes 1–5), while the other
was transferred to a PVDF membrane under native conditions and
probed for ferritin and Tf using specific antibodies [19,20] (Fig. 2,
lanes 6–15). Autoradiography shows a prominent iron labeled
band consistent with ferritin (Fig. 2, lanes 1–5 and 6–10, black
arrow), and a faster migrating band representing Tf (Fig. 2, lanes
1–5 and 11–15, open arrow) (the lower part of the autoradiograph
is over-exposed to highlight the Tf band). Compared to M17
lysates, the amount of
59Fe bound to ferritin is higher in PrP
C and
PrP
102L lysates, and lower in PrP
D51–89 and PrP
D23–89 lysates
(Fig. 2, lanes 1–5). On the other hand, Tf bound iron is higher in
M17 compared to PrP
C, PrP
D51–89, and PrP
D23–89 lysates, and
equivalent to PrP
102L lysates (Fig. 2, lanes 1–5 and 11–15). The
slower migrating iron labeled bands (*) probably represent a
complex of Tf and TfR (Fig. 2, lanes 1–5) [20,21]. Probing for
ferritin shows a major band and minor slower migrating forms
probably representing ferritin complexes (Fig. 2, lanes 6–10, black
arrow). Probing for Tf shows oligomers or glycosylation variants of
Tf that correspond to
59Fe labeled purified transferrin fractionated
similarly (Fig. 2, lanes 1–5, 11–15; Fig. S1). The relative levels of
ferritin and Tf proteins in the samples correspond to radioactive
iron in labeled ferritin and Tf bands in all samples (Fig. 2, lanes 1–
15). Similar results were obtained when the cells were labeled with
59FeCl3-citrate complex for 16 hours or with purified
59Fe-Tf for 4
and 16 hours (data not shown), indicating similar uptake of non-
transferrin and Tf bound Fe by these cells. Silver staining of re-
hydrated autoradiographed gel confirms equal loading of protein
for all samples analyzed (Fig. S1). Quantitative comparison of
ferritin iron and levels of PrP, ferritin, and Tf between the cell lines
is shown below in Fig. 4.
The identity of iron labeled bands in Fig. 2 was further
confirmed by cutting each band from fractionated PrP
C lysates
and re-fractionating electro-eluted proteins on SDS-PAGE
followed by immunoblotting (Fig. S2). Lane 1 represents proteins
eluted from the loading well that did not enter the running native
gel. Lanes 2, 3 and 5 represent iron labeled bands that resolve
adequately on native gels, and lane 4 represents unlabeled section
of the gel that serves as a negative control. Sequential
immunoreaction with specific antibodies confirms the presence
of PrP in band 1, TfR in bands 1 and 2, ferritin in band 3, and Tf
in band 5 (Fig. S2). Band 4 does not react with antibodies to
known iron binding proteins. Silver staining shows co-migration of
a few other un-identified proteins with bands 1–3, and almost
none with bands 4 and 5 (Fig. S2).
To determine if PrP
C mediates iron uptake directly, a modified
non-denaturing gel system with a 3–9% gradient was used to
separate
59Fe-labeled PrP effectively. Accordingly, M17 and PrP
C
cells were radiolabeled with
59FeCl3-citrate complex for 4 hours as
above, and lysates were fractionated in duplicate under non-
denaturing conditions. One part was dried and exposed to an X-
ray film, while the other was transferred to a PVDF membrane
and probed for PrP, ferritin, TfR, and Tf. As in Fig. 2, the amount
of
59Fe incorporated by ferritin in PrP
C cells is significantly higher
than M17 cells (Fig. 3A, lanes 1 and 2, black arrow). A slower
migrating
59Fe labeled band corresponding to Tf/TfR complex is
detected in M17 lysates (Fig. 3A, lanes 1, 7, and 9, open arrow).
Unlike Figure 2, PrP is resolved on this less concentrated gel
system and is detected by PrP specific antibody 3F4 (Fig. 3A, lane
4, arrow-head). However, a corresponding
59Fe labeled band is
not detected in lane 2, though pure
59Fe-labeled recombinant PrP
is readily detected by this method as demonstrated previously [17].
Evaluation of iron modulating proteins shows higher levels of
ferritin and lower levels of TfR and Tf in PrP
C lysates relative to
M17 as in Fig. 1 above (Fig. 3A, lanes 5–10, arrow-head). Ferritin
and Tf/TfR complex show corresponding iron labeled bands as
expected (Fig. 3A, compare lanes 1, 2 with 5, 6, 9, 10).
Fractionation of the same samples by SDS-PAGE followed by
immunoblotting confirms increased levels of ferritin and decreased
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C lysates compared to M17 controls
(Fig. 3B, lanes 1 and 2). Together, these results demonstrate that
PrP
C increases total cellular iron, ferritin iron, and ferritin levels,
and decreases Tf and TfR levels. However, the absence of
59Fe-
labeled PrP
C indicates that either the association of PrP with
59Fe
is transient or relatively weak and disrupted after cell lysis, or
alternatively, PrP facilitates the incorporation of
59Fe into ferritin
by an indirect mechanism that does not involve the formation of a
PrP-iron complex.
To evaluate if expression of PrP
C on the cell surface is required
for iron uptake, a similar evaluation was carried out in cells
expressing PrP
231stop that lacks the GPI anchor and is secreted into
the medium. Radiolabeling of M17, PrP
C, and PrP
231stop cells with
59FeCl3-citrate complex for 4 hours shows significantly more
59Fe-
ferritin in PrP
C cells compared to M17 as above, and minimal
change in PrP
231stop samples (Fig. 3C, lanes 1–3, black arrow).
Western blotting of M17, PrP
C, and PrP
231stop lysates and medium
sample from PrP
231stop cells cultured overnight in serum-free
medium with 3F4 shows the expected glycoforms of PrP in PrP
C
lysates, and undetectable reactivity in M17 and PrP
231stop lysates
as expected (Fig. 3D, lanes 1–3). However, significant reactivity is
detected in the medium of PrP
231stop cells, demonstrating adequate
Figure 1. Cells expressing normal and mutant PrP forms incorporate different levels of iron. (A) Diagrammatic representation of PrP
C
and mutant PrP forms evaluated in this study. (B) Lysates of M17, PrP
C, PrP
D51–89, PrP
D23–89, and PrP
102L were resolved by SDS-PAGE and
immunoreacted for PrP and b-actin. All transfected cell lines express 6–7 fold higher levels of PrP relative to non-transfected M17 cells (lanes 1–5). (C)
Cell lines in (B) were radiolabeled with
59FeCl3-citrate complex, washed with PBS supplemented with 100 mM DFO to chelate surface bound iron, and
lysed. Equal amount of protein from each sample was spotted on a PVDF membrane, air dried, and exposed to an X-ray film.
doi:10.1371/journal.pone.0004468.g001
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231stop in transfected cells (Fig. 3D,
lane 4) [22,23]. Re-probing of lysate samples for ferritin, Tf, and
TfR shows increased levels of ferritin and decreased levels of Tf
and TfR in PrP
C samples compared to M17 lysates (Fig. 3E, lanes
1 and 2). PrP
231stop lysates show minimal change in ferritin levels,
and surprisingly, lower levels of Tf and TfR relative to M17 lysates
(Fig. 3E, lanes 1 and 3). This observation is surprising since
59Fe-
ferritin levels in PrP
231stop cells are as low as M17, and yet the cells
do not show increased levels of Tf and TfR as in M17-cells.
Reaction for b-actin confirms equal loading of protein in all
samples (Fig. 3E, lanes 1–3).
Quantitative comparison of ferritin iron and levels of ferritin,
Tf, and TfR shows significant differences between cell lines. Thus,
relative to M17 cells, PrP
C cells show an increase in ferritin iron
and ferritin levels to 570 and 565%, and a decrease in Tf and TfR
levels to 70 and 75% respectively. A similar comparison of mutant
cell lines relative to PrP
C cells shows the following: PrP
D51–89 cells
show a decrease in ferritin iron and ferritin to 7.0, 6.9%, and
insignificant change in Tf and TfR levels. PrP
D23–89 cells show a
similar decrease in ferritin iron and ferritin levels to 7.5 and 7.2%,
an increase in Tf to 120%, and insignificant change in TfR levels.
PrP
102L-cells show a decrease in ferritin iron and ferritin levels to
89 and 90%, and an increase in Tf and TfR levels to 300 and
142% respectively. PrP
231stop cells show a decrease in ferritin iron
and ferritin to 27 and 16%, and a decrease in Tf and TfR levels to
89 and 67% respectively. Quantification of PrP expression relative
to M17 shows levels of 650, 710, 750, 610, and 5% in PrP
C,
PrP
D51–89, PrP
D23–89, PrP
102L, and PrP
231stop cells respectively
(Fig. 4).
Considering the tightly orchestrated and coordinated balance
between cellular iron levels and iron uptake and storage proteins
[18,21], these results indicate a mild iron overload in PrP
C-cells
relative to M17-cells, and an indefinable phenotype in mutant cell
lines since the iron uptake proteins Tf and TfR do not respond to
ferritin iron levels as expected. Since Tf and TfR levels are
reflective of the biologically available intracellular labile iron pool
(LIP) that is maintained within the physiological range by ferritin,
these results indicate a disconnect between ferritin iron and the
cellular LIP, or a failure of the iron regulatory loop involving the
LIP, iron binding proteins 1 and 2, TfR, and ferritin to induce
appropriate response.
Mutant PrP forms influence the uptake of iron by ferritin
The influence of normal and mutant PrP forms on intracellular
LIP was evaluated in M17 and transfected cell lines cultured in
complete medium under normal culture conditions. All cell lines
were loaded with the iron binding dye calcein-AM, and the increase
in fluorescence in response to salicylaldehyde isonicotinoyhydra-
zone (SIH), a cell permeable iron chelator, was measured (Fig. 5A)
[24]. Relative to M17 cells, PrP
C cells show an increase in LIP to
143%, an expected observation since the ferritin iron levels of these
cells are also higher than M17 cells (compare Figs. 5A and 4). A
similar evaluation of mutant cell lines relative to PrP
C-cells shows a
decrease in LIPto 95, 78 and 67% in PrP
D51–89, PrP
D23–89, PrP
102L-
cells, and an increase to 155% in PrP
231stop cells respectively
(Fig.5A). Theseresultsindicatethat Tfand TfRlevelsinmutantcell
lines observed in Fig.4 above respond to the LIP rather than ferritin
iron content as expected. More importantly, these results indicate a
block in uptake or increased uptake of iron by ferritin in specific cell
lines, accounting for the disproportionate levels of ferritin iron and
intracellular LIP, and the unexpected response of Tf and TfR to
cellular iron content.
To evaluate if the difference in ferritin iron content of different
cell lines is maintained in the presence of excess extra-cellular iron,
M17, PrP
C, PrP
D51–89, PrP
D23–89, PrP
102L, and PrP
231stop-cells
were cultured overnight in the presence of 0.1 mM ferric
ammonium citrate (FAC). (This dose of FAC was found to cause
,1% cell death after overnight exposure). After washing the cells
Figure 2. PrP influences iron incorporation in cellular ferritin. Radiolabeled lysates were fractionated on a 3–20% native gradient gel in
duplicate. One set was subjected to autoradiography (lanes 1–5) and the other was transblotted and probed for ferritin and transferrin under native
conditions (lanes 6–15).
doi:10.1371/journal.pone.0004468.g002
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59Fe-labeled M17 and PrP
C lysates
were fractionated on a 3–9% native gradient gel and auto-radiographed (lanes 1 and 2), or immunoblotted as above with antibodies specific to PrP,
ferritin, TfR, and Tf (lanes 3–10). (B) Immunoblotting of the same samples following fractionation by SDS-PAGE shows similar differences in the levels
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bound iron, cells were disrupted with glacial acetic acid and equal
amount of protein from each cell line was spotted on a PVDF
membrane. Reaction with Ferene-S, a dye that forms a blue
reaction product with iron [25], shows a marked increase in
protein bound iron in all cell lines compared to unexposed controls
(Fig. 5B). More importantly, each cell line reflects cell-specific
differences in protein bound iron as observed for ferritin iron
above (Fig. 5B). Fractionation of lysates by SDS-PAGE followed
by immunoblotting for PrP, ferritin, and TfR shows up-regulation
of PrP and ferritin, and down-regulation of TfR to undetectable
levels in FAC exposed lysates (Fig. S3 A, lanes 1–4) [17]. Up-
regulation of PrP in response to FAC appears to be at the mRNA
level (Fig. S3 B). These results suggest a dominant role for PrP in
the transport of extracellular iron to ferritin both under normal
culture conditions and in the presence of excess extra-cellular iron.
Together, the above results demonstrate a state of relative iron
overload in PrP
C-cells compared to M17 controls as indicated by
an increase in intracellular LIP and iron content of ferritin,
increase in iron storage protein ferritin, and decrease in iron
uptake proteins Tf and TfR. Relative to PrP
C-cells, mutant PrP
expressing cells show a substantial decrease in ferritin iron in
PrP
D51–89, PrP
D23–89, and PrP
231stop-cells, and relatively less
reduction in PrP
102L-cells. Intracellular LIP is reduced in
PrP
D23–89 and PrP
102L, minimally altered in PrP
D51–89, and
substantially increased in PrP
231stop-cells relative to PrP
C-cells. Tf
and TfR respond to LIP levels in some cell lines, but show an
unexpected change in others, reflecting a state of cellular iron
imbalance.
Stimulation of PrP endocytosis increases, and cross-
linking decreases ferritin iron content
Further support for the role of PrP in mediating cellular iron
uptake was obtained by assessing iron incorporation into ferritin
following stimulation or disruption of PrP
C endocytosis by 3F4, a
well characterized monoclonal antibody specific for methionine
residues 109 and 112 of human PrP [26]. A similar approach has
been used successfully to down-regulate mouse PrP using Fab
fragments of PrP specific antibodies [27]. Initial evaluation
revealed that 3F4 concentrations of 1 and 12 mg/ml are optimal
for stimulating and disrupting endocytosis of PrP
C respectively
without compromising cell viability.
Figure 4. Quantitative analysis of the results in Figures 1–3. Quantitative evaluation after densitometry of ferritin iron and levels of PrP,
ferritin, Tf, and TfR in PrP
C, PrP
D51–89, PrP
D23–89, PrP
102L, PrP
231stop-cells relative to non-transfected M17 controls. Values are mean6SEM of 11
independent experiments. The y-scale is linear but has been re-scaled after the break to illustrate the data clearly. For M17 vs. PrP
C *p,0.001,
**p,0.01, and for PrP
C vs. mutant cell lines
#p,0.001,
##p,0.01).
doi:10.1371/journal.pone.0004468.g004
of PrP, ferritin, Tf, and TfR as in (A) after normalization with actin (lanes 1 and 2). (C)
59Fe-labeled M17, PrP
C, and PrP
231stop lysates were fractionated
by native gel electrophoresis and subjected to autoradiography (lanes 1–3). (D) Unlabeled lysates prepared from M17, PrP
C, and PrP
231stop lysates,
and methanol precipitated proteins from the medium sample of PrP
231stop cells were fractionated by SDS-PAGE and immunoblotted for PrP using 3F4
(lanes 1–4). (E) Membrane from (D) was re-probed for ferritin, Tf, TfR, and b-actin (lanes 1–3).
doi:10.1371/journal.pone.0004468.g003
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M17 and PrP
C-cells exposed to 1 mg/ml of 3F4 for 5 days were
fixed, permeabilized, and reacted with anti-mouse-FITC. Both
M17 and PrP
C-cells show minimal reactivity at the plasma
membrane, but significant reactivity in endocytic vesicles that are
more prominent in PrP
C cells (Fig. 6A, panels 1 and 2, arrow-
head). These observations suggest significant endocytosis of PrP
C
along with 3F4. Untreated PrP
C-cells reacted with 3F4-anti-
mouse-FITC show punctuate reaction at the plasma membrane
and minimal intracellular reaction as expected for normal
distribution of PrP
C (Fig. 6A, panel 3, arrow). Exposure to
12 mg/ml of 3F4, however, cross-links PrP
C at the plasma
membrane and reduces its endocytosis significantly (Fig. 6B,
panels 1 and 2). As a control, mouse neuroblastoma cells (N2a)
Figure 5. Cells expressing normal and mutant PrP forms show differential levels of LIP and uptake of extra-cellular iron. (A)
Indicated cell lines were loaded with calcein and intracellular LIP was estimated by quantifying the SIH chelatable iron pool. Values are mean6SEM.
n=12 for M17 and PrP
C, and 7 for mutant cell lines. *p,0.001, **p,0.01,
#p,0.001,
##p,0.01. (B) The same cell lines were exposed to 0.1 mM FAC
for 16 hours and 50 mg of protein from cell homogenates was spotted on a PVDF membrane and reacted with Ferene-S, a dye that forms a blue
reaction product with iron [25].
doi:10.1371/journal.pone.0004468.g005
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C-cells to different concentrations of 3F4 induces endocytosis or cross-linking of PrP. (A) Immunostaining of
M17 and PrP
C cells exposed to 1 mg/ml of 3F4 for 5 days shows a prominent reaction in vesicular structures in M17 and PrP
C cells (panels 1 and 2).
Coalesced vesicles simulating aggregated PrP
C are evident near the Golgi region and in the cytosol of PrP
C cells (panel 2). Untreated PrP
C-cells reacted
with 8H4-anti-mouse-FITC show a prominent reaction at the plasma membrane as expected (panel 3). (B) Reaction of M17 and PrP
C cells exposed to
12 mg/ml of 3F4 for 4 hours with anti-mouse FITC shows cross-linking of PrP on the plasma membrane of M17 and PrP
C cells (panels 1 and 2, arrow)
and a slight increase of reactivity in vesicular structures in the latter (panel 2, arrow-head). Similar exposure of N2a-cells to 3F4 and PrP
C-cells to anti-
Thy1 antibody followed by immunoreaction with 8H4-anti-mouse-FITC shows plasma membrane and Golgi reaction of endogenous PrP in N2a cells
(panel 3) and plasma membrane distribution of PrP in Thy-1 exposed cells (panel 4). (Mouse PrP expressed by N2a cells does not react with 3F4).
doi:10.1371/journal.pone.0004468.g006
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to 3F4 and reacted with mouse PrP-specific antibody 8H4
followed by anti-mouse-FITC. Examination shows normal
distribution of PrP
C at the plasma membrane and some reactivity
in the Golgi region as expected (Fig. 6B, panel 3) [26]. Exposure of
PrP
C cells to anti-Thy-1, a monoclonal antibody to an irrelevant
GPI-linked protein abundant on neuronal cells shows normal
distribution of PrP
C when reacted with 8H4-anti-mouse-FITC
(Fig. 6B, panel 4), confirming the specificity of 3F4 mediated
endocytosis and cross-linking of PrP
C.
The effect of increased endocytosis of PrP
C on ferritin iron
content was evaluated by radiolabeling cells cultured in the
presence of 1 mg/ml of 3F4 with
59FeCl3 for the last 4 hours of the
incubation, and analyzing radiolabeled lysates as in Figure 1
above. Fractionation by non-denaturing page shows a significant
increase in ferritin iron in the 3F4 exposed lysate compared to
untreated control (Fig. 7A, lanes 1 and 2, open arrow). Analysis by
SDS-PAGE and immunoblotting shows 2–3 fold increase in
reactivity for all PrP glycoforms with anti-PrP antibodies 3F4 and
8H4 (Fig. 7A, lanes 3–6). However, the 18 kDa fragment that
results from recycling of PrP
C from the plasma membrane is not
increased in 3F4 exposed lysates, indicating stimulation of PrP
C
internalization and possible intracellular accumulation by 3F4
binding rather than increased recycling from the plasma
membrane (Fig. 7A, lanes 5 and 6) [28]. The 50 kDa band
represents internalized 3F4 (Fig. 7A, lanes 4 and 6). Immunoblot-
ing for ferritin, Tf, and TfR shows an increase in TfR, and
minimal change in ferritin and Tf levels (Fig. 7A, lanes 7 and 8).
Quantification by densitometry shows an increase in ferritin iron
to 271%, and insignificant change in ferritin and Tf levels by 3F4
treatment. The increase in TfR levels to 175% is probably due to
co-endocytosis with PrP-antibody complex (Fig. 7B). Measurement
of cellular LIP revealed insignificant difference between 3F4
exposed and untreated controls after 24 hours (data not shown) or
5 days of treatment, indicating efficient transport of iron to ferritin
within this time frame (Fig. 7C). PrP
C cells treated with anti-Thy-1
antibody, however, demonstrated a significant decrease in LIP
after 5 days of incubation with 3F4 (Fig. 7C).
A similar evaluation of cells exposed to 12 mg/ml of 3F4 for
4 hours shows significantly less increase in ferritin iron compared
to untreated controls (Fig. 8A, lanes 1 and 2, open arrow).
Separation by SDS-PAGE and immunoblotting shows increase in
PrP reactivity (Fig. 8A, lane 4) and an increase in the levels of
ferritin, Tf, and TfR (Fig. 8A, lanes 5 and 6). Quantification shows
an increase in ferritin iron to 148%, and an increase in the levels of
ferritin and TfR to 153 and 146% respectively. Tf levels show
insignificant change by this treatment (Fig. 8B). A similar increase
in ferritin iron is observed when M17 cells expressing endogenous
levels of PrP are exposed to 3F4 (Fig. S4 lanes 1 and 2), ruling out
the effect of over-expression of PrP
C on these observations.
Exposure to equivalent amounts of anti-Thy-1 does not alter
ferritin iron content significantly (Fig. S4, lane 3). Measurement of
intracellular LIP after 4 hours of exposure to 12 mg/ml of 3F4
shows an increase to 170% in treated cells compared to untreated
controls. Exposure to similar concentrations of anti-Thy-1 shows a
decrease to 70% (Fig. 8C), an unexpected effect that requires
further evaluation.
The above results indicate that stimulation of PrP
C endocytosis
over a prolonged period increases iron incorporation into ferritin,
whereas cross-linking of PrP
C that is likely to result in its
degradation following endocytosis has relatively less effect on
ferritin iron. The increase in intra-cellular LIP by cross-linking PrP
without any increase in ferritin iron probably reflects inefficient
transport of iron to ferritin in the absence of PrP, as observed for
certain mutant forms of PrP. The levels of ferritin, Tf, and TfR
probably reflect an artifactual change due to membrane
perturbation by antibody treatment rather than a response to
intracellular LIP.
PrP does not modulate release of iron from cells
To determine if the difference in cellular iron levels between cell
lines is due to differential release into the medium, M17, PrP
C,
PrP
D51–89, PrP
D23–89, and PrP
102L cells were cultured in the
presence of
3H-thymidine overnight to monitor cell proliferation
and radiolabeled with
59FeCl3 for 4 hours as above. Labeled cells
were washed with PBS containing 100 mM DFO to remove
surface bound
59Fe, and chased in complete medium for
30 minutes to 16 hours. At the indicated times equal aliquots of
medium were retrieved and released
59Fe was quantified in a c-
counter. Kinetic analysis shows minimal difference in extracellular
iron between cell lines after normalizing with
3H-thymidine
(Fig. 9A). Estimation of cell-associated
59Fe after 16 hours of chase
shows more
59Fe in PrP
C and PrP
102L, and significantly less in
PrP
D51–89 and PrP
D23–89 compared to M17 lysates as observed in
Fig. 1 above (Fig. 9B). However, the fold difference in ferritin iron
content between M17 and other cell lines is significantly less after
16 hours of chase, and represents steady state levels of iron content
in each cell line. Evaluation of possible ferroxidase activity of
recombinant PrP using plasma as a positive control yielded
negative results (Fig. 9C). Though informative, this result does not
rule out possible ferroxidase activity of cell-associated PrP, a
technically challenging assay that has yielded inconclusive results
(data not shown).
Discussion
The results presented in this report demonstrate an unprece-
dented role of PrP in facilitating iron uptake by cells and its
transport to cellular ferritin. Using a combination of neuroblas-
toma cell lines expressing normal and mutant PrP forms, we
demonstrate that over-expression of PrP
C increases intracellular
LIP and the amount of iron deposited in ferritin. Pathogenic and
non-pathogenic mutations of PrP over-expressed to the same
extent as PrP
C alter cellular LIP and ferritin iron content
differentially, specific to the mutation. Certain cell lines, especially
cells expressing anchorless PrP
231stop, demonstrate increased LIP
in the presence of decreased ferritin iron, while PrP
102L-cells
display low LIP in the presence of adequate ferritin iron.
Furthermore, stimulation of endocytosis by PrP specific antibody
increases ferritin iron, while cross-linking at the plasma membrane
increases LIP but has minimal effect on ferritin iron, indicating
that alteration of PrP function or cellular localization disturbs the
homeostasis between ferritin iron and cellular LIP. The differential
incorporation of iron by mutant cell lines is maintained in the
presence of excess extra-cellular iron, demonstrating a dominant
role of PrP
C in iron uptake and transport. The positive effect of
PrP
C on cellular iron is mainly due to enhanced uptake since the
amount released into the culture medium is not altered in any of
the cell lines tested. Together, these observations suggest a role for
PrP
C in mediating iron uptake and transport to ferritin directly, or
by interacting with other iron modulating proteins. Below we
discuss these data with reference to possible functions of PrP
C in
cellular iron metabolism, and the implications thereof in inducing
imbalance in iron homeostasis observed in prion disease affected
brains [15,16, 45].
It is surprising that a GPI-linked protein such as PrP
C is
involved in iron transport to ferritin since PrP
C is a membrane
protein that undergoes vesicular transport while ferritin is cytosolic
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PLoS ONE | www.plosone.org 9 February 2009 | Volume 4 | Issue 2 | e4468Figure 7. Endocytosis of PrP increases ferritin iron content. (A) PrP
C-cells exposed to 1 mg/ml of 3F4 for 5 days were radiolabeled with
59FeCl3
for 4 hours, and lysates were fractionated on a non-denaturing gel and auto-radiographed (lanes 1 and 2). Equal aliquots of the same samples were
boiled in SDS-containing sample buffer and fractionated in duplicate by SDS-PAGE followed by immunoblotting with PrP specific antibodies 3F4 and
8H4 (lanes 3–6). Subsequently, the membranes were re-probed for ferritin, Tf, TfR, and b-actin (lanes 7 and 8). (B) Quantification by densitometry
shows an increase in ferritin iron and TfR levels, and insignificant change in Tf levels in 3F4 exposed cells. Values are mean6SEM of three independent
experiments. *p,0.001 compared to untreated cells. (C) Estimation of LIP after exposing the cells to 1 mg/ml of 3F4 or anti-Thy-1 antibody for 5 days
shows insignificant difference between untreated and 3F4 treated PrP
C cells, and a decrease in anti-Thy-1 treated cells. *p,0.001. n=5.
doi:10.1371/journal.pone.0004468.g007
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PLoS ONE | www.plosone.org 10 February 2009 | Volume 4 | Issue 2 | e4468Figure 8. Cross-linking of PrP has minimal effect on ferritin iron content. (A) PrP
C-cells exposed to 12 mg/ml of 3F4 for 4 hours were
radiolabeled with
59FeCl3 in the last 2 hours, and lysates were fractionated on a native gel followed by autoradiography (lanes 1 and 2). Equal aliquots
of lysates were fractionated by SDS-PAGE as above and immunoblotted with 3F4 (lanes 3 and 4). The membrane was re-pobed for ferritin, Tf, TfR, and
b-actin (lanes 5 and 6). (B) Quantification by densitometry shows an increase in ferritin iron, ferritin, and TfR levels, and insignificant change in Tf
levels by 3F4 treatment. *p,0.001, **p,0.025. n=3. (C) Estimation of LIP after exposing the cells to 12 mg/ml of 3F4 or anti-Thy-1 antibody for
4 hours shows an increase in 3F4 exposed cells, and a decrease in anti-Thy-1 treated cells. *p,0.001. n=7.
doi:10.1371/journal.pone.0004468.g008
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PLoS ONE | www.plosone.org 11 February 2009 | Volume 4 | Issue 2 | e4468Figure 9. PrP is not involved in the export of iron from cells. (A) Cells expressing PrP
C, PrP
D51–89, PrP
D23–89, and PrP
102L were radiolabeled with
59FeCl3, washed with PBS supplemented with DFO, and chased in complete medium for 30, 60, 90, 120 min, and 16 hours. At the indicated time
points equal aliquots of medium samples were quantified in a c-counter. Estimation of released
59Fe does not show a significant difference between
the indicated cell lines at any time point. n=6 experiments in triplicate. (B) Cell associated
59Fe after 16 h of chase reflects the ferritin iron content of
each cell line noted in Figure 1 above, though the difference between cell lines is significantly less. (C) Possible ferroxidase activity of recombinant
PrP was measured using the established colorimetric method [44] with modifications. Negative controls included water and albumin supplemented
with copper, and positive controls included plasma in the absence or presence of copper. Recombinant PrP does not show detectable ferroxidase
activity either in the absence or presence of copper, whereas plasma shows a robust reaction under similar conditions.
doi:10.1371/journal.pone.0004468.g009
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PLoS ONE | www.plosone.org 12 February 2009 | Volume 4 | Issue 2 | e4468[29]. Normally, cellular iron uptake is mediated by the Tf/TfR
dependent and independent pathways, the former being most
prominent and well characterized especially in neuroblastoma
cells. In the Tf/TfR dependent pathway, ferric iron captured by
Tf is taken up by the cells through TfR-mediated uptake via
clathrin coated pits. Tf-bound ferric iron is released in the acidic
environment of the endosomes, reduced to ferrous iron by an
endosomal ferric reductase Steap3, and transported across the
endosomal membrane by DMT1 to cytosolic ferritin where it is
oxidized to the fairly inert ferric form by ferritin H-chain and
stored [18,19,29]. In the Tf-independent pathway, iron is taken up
by an unknown transport mechanism, possibly non-specifically by
fluid phase of endocytosis, and stored in ferritin. Ferritin regulates
the biologically available LIP in the cell, and is itself regulated by
iron regulatory proteins (IRPs) 1 and 2 [18,19,30,31]. In
neuroblastoma cells, the LIP is a function of total cellular iron,
and an increase in cellular iron is accompanied by increased
ferritin content to maintain the LIP within safe limits [32,33].
Where might PrP intersect with this tightly orchestrated
mechanism of iron uptake, transport, and storage? Three potential
mechanisms are plausible: 1) modulation of uptake at the plasma
membrane independently or by interacting with the Tf/TfR
dependent pathway, 2) facilitation of iron transport to cytosolic
ferritin across the endosomal membrane by promoting ferric iron
release from Tf and/or its reduction for transfer through DMT1
[19], or 3) assistance in deposition into ferritin by oxidizing ferrous
iron to the ferric form. It is unlikely that PrP facilitates export of
iron from neuroblastoma cells based on our observations.
At the plasma membrane, PrP
C could take up iron directly from
the extra-cellular milieu and deliver to an endosomal compart-
ment as suggested for copper [34]. However, this seems unlikely
for three reasons; 1)
59Fe-labeled PrP
C could not be detected in
radiolabeled cells although labeled recombinant PrP is easily
detected using the same procedure [17], 2)
59Fe-labeled recom-
binant PrP loses its label to Tf when added to cells, indicating
lower affinity for iron relative to Tf (unpublished observations),
and 3) intra-cellular LIP is high in cells expressing anchorless
PrP
231stop despite low ferritin iron content, indicating efficient
uptake of iron in the absence of cell surface PrP
C. It remains
plausible, though, that PrP
C modulates iron uptake by the Tf/TfR
pathway at the plasma membrane or in an endosomal compart-
ment [35].
It is also possible that extracellular iron induces the movement
of PrP
C from detergent insoluble membrane domains where it
normally resides to the proximity of TfR in a similar manner as in
the presence of copper [34]. Here, it may enhance the binding of
iron loaded Tf to its receptor, or stimulate the endocytosis of Tf/
TfR complex by a direct or an indirect interaction. In this context,
it is interesting to note that PrP
C undergoes endocytosis through
clathrin coated pits after associating with a transmembrane protein
through its N-terminal domain [36], suggesting that the reported
co-localization of PrP
C with Tf and TfR within endosomes may
reflect a functional association rather than co-residence due to a
common mode of endocytosis [37]. Assuming this scenario, the
increase in TfR levels by stimulation of PrP endocytosis by 3F4
and the differential effect of mutant PrP forms on ferritin iron
content may be explained by a change in the rate of endocytosis,
or altered interaction of normal and mutant PrP forms with Tf or
TfR due to misfolding [35–37]. We have previously reported
increased endocytosis and defective recycling of mutant PrP
102L in
neuroblastoma cells [38], a fact that may account for increased
ferritin iron in these cells. Though attractive, this model fails to
explain decreased ferritin iron in the presence of significantly high
LIP in cells expressing anchorless PrP
231stop and by cross-linking
PrP at the plasma membrane, indicating a role downstream from
the plasma membrane. The up-regulation of PrP
C at the
transcriptional and translational level when cells are exposed to
excess extra-cellular iron (supporting information) perhaps reflects
its function as an iron regulatory protein, though a protective
response to oxidative stress cannot be ruled out under these
experimental conditions [39]. However, since all cell lines display
similar differences in
59Fe-ferritin content when labeled with
59FeCl3 or purified
59Fe-Tf (unpublished observations), it is likely
that PrP
C functions downstream of the iron uptake pathways
specific for free and Tf bound iron, perhaps in an endosomal
compartment.
Keeping the above facts in mind, it is plausible that PrP
C
functions as a ferric reductase along with Steap3 to facilitate the
transport of ferric iron released from Tf across the endosomal
membrane to cytosolic ferritin. This assumption is supported by
the fact that PrP
C functions as a copper transport protein by
reducing copper (II) prior to transfer to copper (I) specific
trafficking proteins within cells [34]. Such a function would
explain the low ferritin iron content in cells expressing mutant PrP
lacking the octapeptide region responsible for reducing copper (II)
[34], the observed up-regulation of PrP
C in response to exogenous
iron, increase in ferritin iron by increased expression of PrP
C and
stimulation of PrP endocytosis, and co-localization of PrP
C and
ferritin in cells exposed to excess iron [17]. However, decreased
ferritin iron despite high LIP levels in cells expressing anchor-less
PrP and the opposite scenario in PrP
102L-cells suggests an
additional role in iron transport between the LIP and cellular
ferritin, a function that is hard to explain merely by the altered
reductase activity of mutant proteins. Although we could not
detect measurable ferroxidase activity of recombinant PrP, such a
function of cell associated PrP
C would explain the facilitative effect
of PrP
C on iron incorporation into ferritin. Further studies are
required to resolve this question.
Despite obvious shortcomings in our data in explaining the
mechanistic details of cellular iron modulation by PrP, this report
clearly shows the effect of PrP and its mutants on iron uptake and
transport. We demonstrate a state of mild iron overload mediated
by PrP
C, and mild iron deficiency or imbalance by pathogenic and
non-pathogenic mutations of PrP. The positive role of PrP
C on
cellular iron levels is further supported by a recent study where
transgenic mice lacking PrP
C expression (PrP
2/2) recover slowly
from experimentally induced hemolytic anemia [40], indicating a
functional role for PrP
C in iron uptake by hematopoietic cells.
These findings take on a greater significance since prion disease
affected human and animal brains show signs of iron imbalance
[45], a potentially neurotoxic state due to the highly redox-active
nature of iron. It is conceivable that dysfunction of PrP due to
aggregation combined with the formation of redox-active PrP
Sc
aggregates [17] induces brain iron imbalance, contributing to
prion disease associated neurotoxicity. Future studies are required
to define the precise biochemical pathway of iron modulation by
PrP, and develop therapeutic strategies to prevent iron induced
neuronal death in prion disorders.
Materials and Methods
Antibodies and chemicals
Monoclonal anti-PrP antibodies 3F4 and 8H4 were obtained from
Signet (Dedham, MA) and Drs. Man-Sun Sy (Case Western Reserve
University) and Pierluigi Gambetti (National Prion Surveillance
Center, Case Western Reserve University) respectively. Antibody
against human ferritin was purchased from Sigma (St. Louis, MO),
anti-transferrin from GeneTex (San Antonio, TX), anti transferrin
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1.1 from eBioscience (SanDiego, CA). Secondary antibodies tagged
with HRP or fluorophores FITC and TRITC were obtained from
Amersham Biosciences (England) and Southern Biotechnology
Associates (Birmingham, AL) respectively. Ferrous ammonium
sulfate, Ferene S, and all other chemicals were purchased from
Sigma. All cell culture supplies were obtained from Invitrogen.
59FeCl3 was from Perkin-Elmer.
Cell lines and culture conditions
Human neuroblastoma cells (M17) were obtained from J.
Biedler (Memorial Sloan-Kattering Cancer Center, New York)
and purchased from ATCC. M17 cells expressing PrP
C, PrP
231stop,
PrP
D51–89, PrP
D23–89, and PrP
102L were generated and cultured as
described in previous reports [41,42]. For this study M17 cells
from two different sources were transfected at least three separate
times and bulk transfected cells were used to avoid cloning
artifacts. Similarly transfected cells from two different investigators
and cells cultured in DMEM supplemented with 10% FBS and
Opti-MEM supplemented with different lots of FCS were also
tried to avoid errors due to culture conditions.
Radiolabeling with
59FeCl3
M17, PrP
C, and mutant PrP
D51–89, PrP
D23–89, PrP
102L, and
PrP
231stop cells cultured overnight to 80% confluency were serum
starved for 1 h and incubated with
59FeCl3-citrate complex (1 mM
sodium citrate and 20–25 mCi of
59FeCl3 in serum free Opti-
MEM; molar ratio of citrate to iron was maintained at 100:1) for
4 h at 37uC in the incubator. At the end of the incubation cells
were washed 3 times with ice cold PBS and lysed with native lysis
buffer (0.14 M NaCl, 0.1 M HEPES, pH 7.4, 1.5% Triton X-100
and 1 mM PMSF). Aliquots of lysates were mixed with glycerol (to
a final concentration of 5%) and traces of bromophenol blue, and
equal amount of protein from each sample was resolved on 3–9%
native gradient gel. For fractionation on SDS-PAGE, the same
samples were mixed with 46 SDS-sample buffer, boiled for
10 min and resolved on SDS-PAGE followed by immunoblotting.
Native gradient gel electrophoresis, autoradiography,
immunoblotting and electroelution
Electrophoresis of lysates was performed using a Hoefer SE 600
vertical apparatus with a cooling system. Linear 3–20% (Fig. 1) or
3–9% (Fig. 3) gradient polyacrylamide gels were prepared as
described by Vyoral et al. [21] with modifications. The gel mixture
contained 0.375 M Tris, pH 6.8, 1.5% Triton X-100, and
1.18 mM ammonium persulfate. N,N,N9,N9-Tetramethylethylene-
diamine (TEMED) was added to a final concentration of 5.38 mM.
Radiolabeled lysates mixed with glycerol were subjected to
electrophoresis using electrode/running buffer (25 mM Tris,
192 mM glycine pH 8.3, and 1.5% Triton X-100) under constant
current (100 mA) for 4 h at 4uC. Gels were either electroblotted or
vacuum dried (BioRad) and exposed to X-ray film (Kodak BioMax
XAR) fitted with intensifying screens. For Western Blotting, gels
were washed thoroughly with electrode buffer without Triton X-
100 for 2 h (each wash of 200 ml, 10 min) on a slowly rocking
platform to remove Triton. The gel was electroblotted to a PVDF
membrane using BioRad semi-dry electroblotting system with
anode buffer (25 mM Tris, pH 10.4) and cathode buffer (25 mM
Tris, 39 mM glycine, pH 9.2) at 25 V for 90 min. Membranes
were further processed for immunodetection as described below.
To confirm the identity of iron labeled proteins, iron bands were
excised from native gels and proteins were electro-eluted using
Biorad electro-eluter at 60 mA for 4 h. Eluted proteins were
concentrated by methanol precipitation and analyzed by SDS-
PAGE.
SDS-PAGE and Western blotting
Cells cultured under different conditions were fractionated by
SDS-PAGE and immunoblotted as described previously [41,42].
The following antibody dilutions were used: 8H4 (1:3000), 3F4
(1:5000), ferritin (1:1000), Tf (1:6000), TfR (1:3000), actin (1:7500),
secondary antibodies conjugated with horseradish peroxidase
(1:6000). Immunoreactive bands were visualized by ECL (Amer-
sham Biosciences Inc.).
Measurement of intracellular calcein-chelatable iron
Cellular labile iron pool (LIP) was assayed as described by
Tenopoulou et al. [43] using the iron sensitive fluorescent dye
calcein. When incubated with cells as a lipophilic calcein-AM-ester
(molecular probes), it enters the cells and is cleaved by cellular
esterases to release calcein that binds iron and is quenched by this
reaction. Upon addition of the cell permeable iron chelator
salicylaldehyde isonicotinoyhydrazone (SIH), iron is released from
calcein that regains its fluorescence (recorded at lex 488 nm and
lem 518 nm). Briefly, 5610
5 M17 cells or cell lines expressing
PrP
C and mutant PrP forms plated in 35 mm Petri dishes were
washed with PBS containing 1 mg/ml BSA and 20 mM Hepes,
pH 7.3 and incubated with 0.25 mM calcein-AM for 20 min at
37uC in same buffer. After calcein loading, cells were trypsinized,
washed and re-suspended in 1.0 ml of the above buffer without
calcein-AM and placed in a 24 well micro-plate in a thermostat-
ically controlled (37uC) fluorescence plate reader (Microtek). The
fluorescence was monitored at lex 488 nm and lem 518 nm. Iron-
induced quenching of calcein was reduced by the addition of
20 mM SIH. Cell number and viability was checked by Trypan
Blue dye exclusion and results were expressed as DF/10
6 cells.
Detection of iron with Ferene S
Cell lines cultured overnight in complete medium or in the
presence of 0.1 mM ferric ammonium citrate (FAC) were washed
with PBS supplemented with EDTA to chelate surface bound iron
and pelleted. The pellet was dissolved in 50 ml of acetic acid and
equal amount of protein (50 mg) was spotted on a PVDF membrane
and immersed in a freshly prepared solution of Ferene S (0.75 mM
3-[2-pyridyl]-5, 6-bis(2-[-furyl sulfonic acid]-2, 4-triazine, 2% (v/v)
acetic acid, 0.1% thioglycolic acid) (24) for 30 minutes at 37uC.
Ferene reacts with iron in the presence of acetic acid and
thioglycolic acid to form a dark blue complex. Stained membranes
were de-stained with 2% acetic acid and scanned.
Stimulation of endocytosis with 3F4 antibody
M17 and PrP
C cells were cultured in DMEM supplemented
with 5% FBS and 1% PSF at 37uC in a humidified atmosphere in
absence or presence of 1 mg/ml of 3F4 for 5 days [26,27]. Medium
containing 3F4 was replaced every 2
nd day and care was taken to
make sure that the cells did not achieve confluency. On the 5
th
day, cells were washed and incubated with serum free DMEM for
1 h, followed by radiolabeling with
59FeCl3-citrate complex in
DMEM for 4 h as above. In a separate experimental paradigm,
N2a, M17 and PrP
C cells were radiolabeled as above in the
presence of 12 mg/ml of 3F4 or Thy-1 4 h. After labeling, cells
were washed, lysed in native lysis buffer, and analyzed as above.
Immunostaining and fluorescence microscopy
Cell lines subjected to different experimental conditions were
processed for immunostaining as described in a previous report [41].
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Cell lines expressing different PrP forms were radiolabeled with
59FeCl3-citrate complex as above. Cell surface bound iron was
chelated with 3 washes of PBS supplemented with DFO (100 mM)
and the cells were chased in complete medium for different time
periods. A 50 ml aliquot of the medium was retrieved at each time
point and counted in a c-counter. After 16 h, cells were lysed and
cell associated iron was measured in a gamma counter.
Estimation of ferroxidase activity of recombinant PrP
Ferroxidase activity of PrP was measured by the published
colorimetric method using 3-(2-pyridyl)-5,6-bis(2-[5furylsulfonic
acid])-1,2,4-triazine that forms a colored Fe
2+ complex with
ferrous iron (44) with the following modifications: Reagent A:
0,45 mol/l sodium acetate, pH 5.8, reagent B: 130 mmol/l
thiourea, 367 mM/l Fe(NH4)(SO4)266H2O, reagent C (chromo-
gen): 18 mmol/l 3-(2-pyridyl)-5,6-bis(2-[5-furylsulfonic acid])-
1,2,4-triazine in 0.01 M Tris pH 7.0. Each sample contained
either 1 ml of water or 1 ml of 300 mM CuSO4,6mL of the sample
(undiluted human plasma, human serum albumin 70 g/l (Sigma
A1653-5G) in PBS or recombinant prion protein (0.6 mg/ml) and
820 ml of reagent A. Multichannel pipette (Finnpipette) was used
for the rapid addition of the reagent B (substrate) to minimize the
time difference in sample processing. Sample quadruplicates were
incubated at 37uC for 4 min. Unoxidized Fe
2+ was reacted with
60 ml of chromogen solution (reagent C) and absorbance was
measured at 600 nm with Smart Spec Plus (BioRad) spectropho-
tometer. Copper was added to provide two copper ions per PrP
molecule, and was also added to human albumin and plasma
samples. The amount of PrP protein in PrP-containing samples
(3.6 mg/sample) roughly corresponds to a known amount of
ceruloplasmin in 6 ml of undiluted human plasma. As a control,
purified 99% human serum albumin was used (70 g/l in PBS) to
mimic the total protein concentration in plasma. As a blank
samples were supplemented with 6 ml of de-ionized water instead
of albumin solution, plasma or recombinant PrP solution.
RNA Isolation and Northern blotting
M17 and WT cells cultured in the absence or presence of
0.1 mM FAC for 24 h were washed with cold PBS, trypsinized,
and collected in 1.5 ml eppendorf tubes. Total RNA was isolated
by using SV total RNA isolation kit (Promega, Madison, WI) and
quantified. 15 mg of total RNA was fractionated on 0.8%
formaldehyde agarose gel followed by blotting to positively
charged Nylon membranes (Roche diagnostics). Membranes were
hybridized with DIG-labeled PrP or b-actin probes and binding
was detected by the CSPD reagent.
Statistical analysis
Data are presented as the mean6SEM values. Statistical
evaluation of the data was performed by using Students t-test
(unpaired).
Supporting Information
Figure S1 (A) Apotransferrin (Sigma) was radiolabeled with
59FeCl3-citrate complex and resolved on a native gel as in Fig. 2.
Tf migrates as three distinct bands representing different
conformational forms. (B) Autoradiographed gel from Figure 2
was re-hydrated and stained with silver to ensure equal loading of
proteins (Beta-actin does not resolve on this native gel).
Found at: doi:10.1371/journal.pone.0004468.s001 (7.48 MB TIF)
Figure S2 Lysates of PrPC cells labeled with 59FeCl3-citrate
complex were resolved on native gel as in Fig. 1 and exposed to an
X-ray film to visualize iron labeled bands (panel A). Marked areas
were excised from the wet gel, proteins were electro-eluted, and
resolved by SDS-PAGE followed by sequential immunoblotting
with antibodies specific to PrP, TfR, ferritin, and Tf (panel B).
Finally, the membrane was stained with silver to visualize all
proteins (panel B). Band 1 that includes proteins in the loading well
reacts strongly for PrP and TfR. Band 3 reacts specifically for
ferritin, while band 5 represents Tf. No detectable proteins are
present in band 4. Silver staining shows 4 prominent proteins in
bands 1–3, the identity of which is currently unknown.
Found at: doi:10.1371/journal.pone.0004468.s002 (10.07 MB
TIF)
Figure S3 (A) Lysates of M17 and PrPC-cells treated as in
Figure 5 were fractionated by SDS-PAGE and transferred proteins
were probed for PrP, ferritin, TfR, and b-actin (lanes 1–4). (B)
FAC exposed M17 and PrPC-cells show up-regulation of PrP
mRNA compared to untreated controls (lanes 1–4).
Found at: doi:10.1371/journal.pone.0004468.s003 (2.03 MB TIF)
Figure S4 M17-cells exposed to buffer, 3F4, and anti-Thy-1
antibody were radiolabeled with 59FeCl3-citrate complex and
lysates were resolved on native gel followed by autoradiography
(lanes 1–3). Equal aliquots of the same samples were resolved by
SDS-PAGE followed by immunoblotting for b-actin to ensure
equal loading of protein (lanes 1–3).
Found at: doi:10.1371/journal.pone.0004468.s004 (1.00 MB TIF)
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